Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D9AH
|
|||
| Former ID |
DCL000260
|
|||
| Drug Name |
VX-702
|
|||
| Synonyms |
ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronary artery disease [ICD-11: BA80; ICD-10: I25.1] | Phase 2a | [1], [2] | |
| Rheumatoid arthritis [ICD-11: FA20] | Phase 2a | [1], [2] | ||
| Inflammation [ICD-11: 1A00-CA43.1] | Phase 1 | [1], [2] | ||
| Company |
Vertex Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H12F4N4O2
|
|||
| Canonical SMILES |
C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F
|
|||
| InChI |
1S/C19H12F4N4O2/c20-9-4-5-10(14(23)8-9)16-11(18(24)28)6-7-15(26-16)27(19(25)29)17-12(21)2-1-3-13(17)22/h1-8H,(H2,24,28)(H2,25,29)
|
|||
| InChIKey |
FYSRKRZDBHOFAY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 745833-23-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
15352551, 22705863, 33974208, 75777633, 85246167, 99436943, 103744977, 103905258, 104148432, 118844927, 121732905, 124757875, 125164677, 125351202, 126584084, 126661323, 126666956, 126728330, 134338917, 134964435, 135330168, 135685273, 135685277, 135685281, 136340266, 136345856, 136367511, 136367730, 137275870, 139348240, 143498842, 152041814, 152234875, 152258201, 152344376, 160647037, 162011763, 162037999, 162205100, 163124118, 164023452, 164044690, 164766153, 164826152, 172849964, 172919863, 174560985, 177748767, 178102680, 180371709
|
|||
| ChEBI ID |
CHEBI:94489
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6059). | |||
| REF 2 | Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. | |||
| REF 3 | Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41. | |||
| REF 4 | Comparative renal excretion of VX-702, a novel p38 MAPK inhibitor, and methotrexate in the perfused rat kidney model. Drug Dev Ind Pharm. 2010 Mar;36(3):315-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.